Updates are available Correction dated 2025-01-17

Article History

Received: 16 August 2024

Accepted: 1 October 2024

First Online: 8 November 2024

Change Date: 17 January 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s13555-024-01328-4

Declarations

:

: Richard B. Warren has received grants from AbbVie, Almirall, Amgen, Celgene, Janssen, Lilly, LEO Pharma, Novartis, and Pfizer. He has received personal fees from AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Avillion, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Janssen, Lilly, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB. Lev Pavlovsky has served as an investigator for AbbVie, Coherus, Novartis Pharmaceuticals Corporation, Janssen Biotech, Eli Lilly, Bristol Myers Squibb and as an adviser, consultant, and/or invited lecturer for AbbVie, Janssen Biotech, Novartis Pharmaceuticals Corporation, Pfizer Inc., Dexcel Pharma, Eli Lilly, and Boehringer Ingelheim. Antonio Costanzo has served as a clinical study investigator for AbbVie, has received research grants and/or speaker/ad board honoraria from AbbVie, Eli Lilly, Amgen, Almirall, Leo Pharma, Novartis, UCB, and Pfizer, and is currently affiliated with ESDR (member), Sidemast (member), and EDF (board member). Michael Bukhalo has received honoraria or fees for serving on advisory boards, as a speaker, as a consultant, and grants as an investigator from Allergan, Boehringer Ingelheim, Celgene, Centocor, DUSA Pharmaceuticals, Eli Lilly, Galderma, Leo Pharma, MedImmune, Merck, and Novartis. Neil J. Korman has served as an investigator, speaker, adviser, or consultant for AbbVie, Abcentra, Amgen, Argenx, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celgene, Chemocentryx, Dermavant, Eli Lilly, Galderma, Janssen, Kyowa Hakko Kirin Pharma, Leo Pharma, Menlo Therapeutics, Novartis, OliX Pharma, Pfizer, Prothena, Principia, Regeneron, Rhizen, Sanofi, Soligenix, Sun Pharma, Syntimmune, Trevi, UCB, and XBiotech. Yu-Huei Huang has conducted clinical trials while serving as a principal investigator for Galderma, Eli Lilly, Novartis Pharmaceuticals Corporation, and Janssen-Cilag Pharmaceutica; received honoraria for serving as an advisory board member for Pfizer Limited, AbbVie, and Celgene; and received speaking fees from AbbVie, Eli Lilly, and Novartis Pharmaceuticals Corporation. Georgios Kokolakis has received travel grants or honoraria, has been a consultant member of advisory boards and speaker bureaus, or has served as an investigator for AbbVie, Actelion, Almirall, Amgen, Basilea, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Hexal-Sandoz, Janssen-Cilag, LEO Pharma, Eli Lilly, MSD, Novartis, Pfizer, Sanofi-Aventis, Stada, Takeda and UCB. Andreas Pinter is an investigator and/or speaker and/or adviser for the following pharmaceutical companies: AbbVie, Almirall-Hermal, Amgen, Biogen Idec, Boehringer Ingelheim, Celgene, GSK, Eli Lilly, Galderma, Hexal, Janssen, LEO Pharma, MC2, Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Sanofi Genzyme, Schering-Plough, UCB Pharma and Zuellig Pharma. Simone Rubant, Nadia Ibrahim, Yanbing Zheng, Leonidas Drogaris, Ahmed M. Soliman, and Vassilis Stakias are full-time employees of AbbVie and may own stock/options or patents. Diamant Thaçi is an adviser, speaker, and/or consultant for AbbVie, Almirall, Amgen, Asana Biosciences, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Galderma, Janssen, Kyowa Kirin, LEO Pharma, Lilly, New Bridge, Novartis, Pfizer, Regeneron, Sanofi/Genzyme, Tamro, UCB, and Zuellig Pharma. He is also involved in research for AbbVie, LEO Pharma, and Novartis.

: Approvals were obtained from local ethics committees, and the patients provided written informed consent. The study was conducted in accordance with the International Conference on Harmonisation, Good Clinical Practice Guidelines, and the Declaration of Helsinki.